0.00

100.00% -12.01

Aeglea BioTherapeutics Inc (AGLE)

Overview News Price History Why AGLE Down? Discussions Forecast Stock Split

Aeglea BioTherapeutics Inc stock is currently priced at $0.00, with a 24-hour trading volume of 0. It has seen a -100.00% decreased in the last 24 hours and a -100.00% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $11.68 pivot point. If it approaches the $9.37 support level, significant changes may occur.

Previous Close:

$12.01

Open:

24h Volume:

Market Cap:

$48.63M

Revenue:

Net Income/Loss:

P/E Ratio:

0.00

EPS:

-71

Net Cash Flow:

1W Performance:

-100.00%

1M Performance:

-100.00%

6M Performance:

-100.00%

1Y Performance:

-100.00%

1D Range:

$0.00

52W Range:

$0.00

$16.58

Aeglea BioTherapeutics Inc Stock (AGLE) Company Profile

Name

Aeglea BioTherapeutics Inc

Sector

Healthcare (1201)

Industry

Biotechnology (688)

Phone

512 942 2935

Address

805 Las Cimas Parkway, Suite 100, Austin, TX

Employee

Twitter

@aegleabio

Next Earnings Date

2023-11-06

Latest SEC Filings

AGLE's Discussions on Twitter

Aeglea BioTherapeutics Inc Stock (AGLE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-04-20	Initiated	Piper Sandler	Overweight
Mar-21-19	Initiated	JP Morgan	Overweight
Sep-04-18	Downgrade	Wells Fargo	Outperform → Market Perform
Apr-24-18	Initiated	Evercore ISI	Outperform
Mar-14-18	Reiterated	Needham	Buy

Aeglea BioTherapeutics Inc Stock (AGLE) Financials Data

There is no financial data for Aeglea BioTherapeutics Inc (AGLE). Check out other stocks for more information.

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.